Coherus Completes $50m Share Offer To Novel Partner Junshi Biosciences
Follows Immuno-Oncology Collaboration Agreement In February
Executive Summary
Coherus BioSciences has sold a little under 2.5 million shares to partner Junshi Biosciences, giving the firm additional capital following a large debt financing last year.
You may also be interested in...
Coherus Bolsters Top Team As It Prepares For Launches
Coherus is laying the pathway for future launches of biosimilars and novel biologics by strengthening its leadership team with a trio of appointments.
Coherus’ Pegfilgrastim Sales Fall $150m In 2021 As Firm Plans On-Body
Coherus BioSciences has posted a massive loss for 2021 due to tumbling revenues, as well as continued investment in its pipeline projects, not least the proposed on-body injector device for its pegfilgrastim biosimilar alongside a ranibizumab asset.
Biosimilars Players Climb Global Rankings
Biosimilars players are gaining an increasing foothold in the off-patent industry, as demonstrated by the final part of our annual Top 50 ranking.